Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs

Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS medicine 2019-07, Vol.16 (7), p.e1002851-e1002851
Hauptverfasser:	Davies, Geraint, Boeree, Martin, Hermann, Dave, Hoelscher, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Abbreviations Antitubercular agents Antitubercular Agents - adverse effects Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Bactericidal activity Bedaquiline Biological markers Biology and Life Sciences Clinical trials Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Collection Review Combination drug therapy Computed tomography Critical path Drug development Drug Development - trends Drug dosages Drug interaction Drug interactions Drug therapy Drug Therapy, Combination Emissions Humans Infectious diseases Liquid culture Medical innovations Medicine and Health Sciences Patient Safety Patients Pharmacodynamics Positron emission tomography Product development Research and analysis methods Research Design - trends Rifampin Rifamycins Rifapentine Risk Assessment Risk Factors Risk reduction Studies Technology Testing Tomography Treatment Outcome Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - microbiology Workflow
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
ISSN:	1549-1676 1549-1277 1549-1676
DOI:	10.1371/journal.pmed.1002851